CO2022008799A2 - Minitrampas de vegf y métodos de uso de las mismas - Google Patents

Minitrampas de vegf y métodos de uso de las mismas

Info

Publication number
CO2022008799A2
CO2022008799A2 CONC2022/0008799A CO2022008799A CO2022008799A2 CO 2022008799 A2 CO2022008799 A2 CO 2022008799A2 CO 2022008799 A CO2022008799 A CO 2022008799A CO 2022008799 A2 CO2022008799 A2 CO 2022008799A2
Authority
CO
Colombia
Prior art keywords
mini
methods
vegf traps
vegf
traps
Prior art date
Application number
CONC2022/0008799A
Other languages
English (en)
Inventor
Joel Martin
Samuel Davis
Shawn Lawrence
Amy Johnson
Meghan Casey
Jaimie Mastrogiacomo
Shunhai Wang
Ning Li
Andrew Tustian
Ankit Vartak
Matthew Franklin
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CO2022008799A2 publication Critical patent/CO2022008799A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona moléculas de minitrampa de VEGF y un método para tratar o prevenir trastornos angiogénicos tal como trastornos oculares angiogénicos y cáncer.
CONC2022/0008799A 2019-12-06 2022-06-24 Minitrampas de vegf y métodos de uso de las mismas CO2022008799A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962944635P 2019-12-06 2019-12-06
PCT/US2020/063238 WO2021113591A1 (en) 2019-12-06 2020-12-04 Vegf mini-traps and methods of use thereof

Publications (1)

Publication Number Publication Date
CO2022008799A2 true CO2022008799A2 (es) 2022-06-30

Family

ID=74046173

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0008799A CO2022008799A2 (es) 2019-12-06 2022-06-24 Minitrampas de vegf y métodos de uso de las mismas

Country Status (13)

Country Link
US (1) US20230063116A1 (es)
EP (1) EP4069264A1 (es)
JP (1) JP2023505216A (es)
KR (1) KR20220110555A (es)
CN (1) CN114786695A (es)
AU (1) AU2020397053A1 (es)
BR (1) BR112022010686A2 (es)
CA (1) CA3163876A1 (es)
CL (1) CL2022001479A1 (es)
CO (1) CO2022008799A2 (es)
IL (1) IL293286A (es)
MX (1) MX2022006751A (es)
WO (1) WO2021113591A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4534972A (en) 1983-03-29 1985-08-13 Miles Laboratories, Inc. Protein compositions substantially free from infectious agents
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7306799B2 (en) * 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7070959B1 (en) * 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
MEP3208A (xx) 1999-06-08 2010-02-10 Regeneron Pharma Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
CN102233132B (zh) * 2010-04-28 2013-10-23 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备抑制眼表新生血管生长的药物中的应用
CA2824422A1 (en) 2011-01-13 2012-07-19 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
US11266745B2 (en) * 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
MX2020003945A (es) * 2017-10-18 2020-11-09 Regenxbio Inc Tratamiento de enfermedades oculares y cancer de colon metastasico con vegf-trap humano modificado post-traduccionalmente .

Also Published As

Publication number Publication date
BR112022010686A2 (pt) 2022-08-23
WO2021113591A1 (en) 2021-06-10
IL293286A (en) 2022-07-01
CN114786695A (zh) 2022-07-22
KR20220110555A (ko) 2022-08-08
US20230063116A1 (en) 2023-03-02
CL2022001479A1 (es) 2023-01-20
CA3163876A1 (en) 2021-06-10
MX2022006751A (es) 2022-08-19
JP2023505216A (ja) 2023-02-08
EP4069264A1 (en) 2022-10-12
AU2020397053A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
BR112021016620A2 (pt) Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
CL2019003114A1 (es) Anticuerpos anti–tau y métodos de uso (divisional solicitud 201703063)
EA201800444A1 (ru) Производные майтанзиноида, их конъюгаты и способы использования
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
CL2020003218A1 (es) Anticuerpos dirigidos contra il-11ra
BR112017000130A2 (pt) método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
CY1124695T1 (el) Κλασματα πλασματος αιματος ως μια θεραπεια για γνωστικες διαταραχες που σχετιζονται με τη γηρανση
CR20190271A (es) Anticuerpos antitau y métodos de uso
CL2021000163A1 (es) Anticuerpos anti-htra1 y metodos de usos de los mismos. (divisional de solicitud 201801139)
DOP2017000254A (es) Imidazopirazinonas como inhibidores de pde1
MX2019011423A (es) Metodos de tratamiento de enfermedades neurodegenerativas.
EA201991818A1 (ru) Лечение рака
BR112018001853A2 (pt) métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio
AR117952A2 (es) Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos mediante su uso
BR112018070497A2 (pt) métodos e formulações farmacêuticas para tratamento de condições oculares
BR112018007566A2 (pt) neuromodulação periférica dependente do estado para tratar disfunção da bexiga
UY38352A (es) Inhibidores de integrina alfavbeta6
BR112021017550A2 (pt) Métodos de tratamento da amiloidose al
CO2022002627A2 (es) Composiciones biofarmacéuticas y procedimientos conexos
CO2022008799A2 (es) Minitrampas de vegf y métodos de uso de las mismas
BR112018013928A2 (pt) composições terapêuticas e métodos para tratamento da hepatite b
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
EA201891351A1 (ru) Вспениваемая композиция галобетазола и способ её применения